We are de-risking biomedical innovation, turning biomedical knowledge into social and economic value.
More than three decades later, we remain committed in pursuit of pharmaceutical innovation, providing high quality products and striving to deliver superior business results.
The patient is at the heart of what we do, making decisions regarding biometric innovation is usually a complicated and chaotic procedure as it consists of various product options, various facets to ascertain these on, and multiple evaluations at all levels.
Discover our therapeutic areas, where we continuously invest to innovate and deliver therapeutic solutions for patient’s benefit.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
16
Sep 2026
Structured exercise may help people with cancer live longer and have more time free of disease, finds a synthesis of the available evidence, published online in the British Journal of Sports Medicine.
16
Sep 2026
Some of the most vulnerable children and young people are failing to get access to mental health support despite much higher levels of need, according to new research from the University of Cambridge.
16
Sep 2026
Oncologists know that intensive treatment rarely helps patients in their final days but recognizing when someone is entering that stage is difficult, especially in metastatic breast cancer, where an increasing number of effective treatments has helped prolong life and given patients and oncologists more treatment options.
16
Sep 2026
Researchers showed that a single high-density ECoG implant could decode attempted speech and upper-body gestures in parallel in people with severe paralysis, allowing two participants to control a personalized full-body avatar. Training the decoders on both isolated and concurrent behaviors improved performance across contexts and reduced false activations, offering proof-of-concept evidence for more expressive multimodal BCIs.